The 8th Guangdong-Hong Kong-Macao Greater Bay Area Biotech Innovation Top 50 Selection has officially commenced. Technoderma Medicines, Inc . (hereinafter referred to as "Technoderma Medicines") was awarded a "Pioneer Enterprise" on th
January 6,2025,Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment in patients with Atopic Dermati
On December 9, 2024, clinical-stage biopharmaceutical company Technoderma Medicines Inc. (hereinafter referred to as "Technoderma") officially announced that its topical ointment TDM-180935, a JAK1/Tyk2 dual-target inhibitor developed for atopic
Technoderma Medicines Advances TDM-180935 Atopic Dermatitis Clinical Program with Phase 2 Trial
CHENGDU – February 5, 2024Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed its Phase 2a clinical trial (NCT05802173) of TDM-105795 topical solution for Androgeneti
Technoderma Medicines, Inc.is a clinical stage biopharmaceutical company.
The company's current core R&D projects include innovative drugs for the treatment of diseases such as androgenetic alopecia, eczema/atopic dermatitis, psoriasis, and systemic lupus erythematosus. Both the TDM-105795 project (for androgenetic alopecia) and the TDM-180935 project (for atopic dermatitis) have completed Phase IIa clinical trials in the United States. The results of these Phase IIa clinical trials have demonstrated positive efficacy, favorable drug tolerance, and good safety profiles. The positive outcomes not only laid a solid foundation for subsequent clinical research and drug development, but also provided important support for technological breakthroughs in the therapeutic fields of these related diseases.
